Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments-Reference-Cited by-同舟云学术

Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments

Published:2022-02-21 Issue:5 Volume:21 Page:865-878
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceutical Statistics

Author:

Huang Bo¹^ORCID,Tian Lu²

Affiliation:

1. Pfizer Inc. Groton Connecticut USA

2. Stanford Medical School, Stanford University Stanford California USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2198

Reference30 articles.

1. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents

2. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials

3. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials

4. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics;2018.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics

5. Committee for Medicinal Products for Human Use.Guideline on the Evaluation of Anticancer Medicinal Products in Man. Rev. 6. EMA; 2020.https://www.ema.europa.eu/en/evaluation-anticancer-medicinal-products-man

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonconcurrent Controls in Platform Trials: Can We Borrow Their Concurrent Observation Data?;Statistics in Biopharmaceutical Research;2023-10-05

2. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study;The Lancet Haematology;2023-10

3. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up;Journal of Clinical Oncology;2023-07-01

4. Assessment of added activity of an antitumor agent;Contemporary Clinical Trials;2022-12

5. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials;Journal of Biopharmaceutical Statistics;2022-11-07